Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.
John Fox
Advertisement
Articles by John Fox
Advertisement
Latest Updated Articles
- 3 Reasons US Payers Will Make 2021 a Banner Year for Biosimilars
November 12th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Launch is Just the Beginning: Rare Disease Care Requires Durability
2
Novartis to Layoff 322 NJ Employees: Report
3
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
4
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
5